Post by Medindia Health Information

Can a 100-year-old pharmaceutical supply chain model support the future of advanced cancer care? In our latest episode of the Medindia Expert Insights Podcast, Dr. Nikita sits down with Dr. Michael Kadan, Chief Operating Officer of Vector Biomed, to discuss why the next big breakthrough in cancer care isn't a scientific one—it's a manufacturing one. While CAR-T cell therapy has shown unprecedented success in treating certain blood cancers, millions of eligible patients globally—particularly in low- and middle-income countries—remain priced out due to centralized production models and massive infrastructure costs. Key takeaways from this episode: 💡 The Shift to Decentralized Manufacturing: Why point-of-care (localized) manufacturing is essential to making cell and gene therapies practical and affordable. 🇮🇳 India as a Launchpad: A look at how localized trials and turnkey clinical setups (like the partnership with the Mohnyisa Ashram) are proving that distributed manufacturing works. 🤝 Beyond Transactional Pharma: How a B-Corp model allows suppliers to partner directly with local healthcare systems to scale access geometrically. Watch the full conversation to learn how we can bridge the global healthcare gap and bring life-saving cancer care directly to the communities that need it most. 📺 Watch here: https://lnkd.in/grbiwMH9 #carttherapy #cellandgenetherapy #immunotherapy #cancercare #healthequity #biotechmanufacturing #digitalhealth #medindia #healthcareinnovation #oncology #globalhealth #pointofcare